Insilico Medicine, a Hong Kong-based firm that uses artificial intelligence (AI) for drug discovery and ageing research, announced on Tuesday that it has raked in $255 million in a Series C round of financing led by US private equity (PE) giant Warburg Pincus.
Continue reading this premium story with a subscription to DealStreetAsia.Subscribe
Already a Subscriber? Log in
Contact us for corporate subscriptions at email@example.com